IGF2BP1

Across TCGA pan-cancer cohorts, IGF2BP1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGF2BP1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher IGF2BP1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGF2BP1 expression acts as an unfavorable survival marker.

CCRCC, UCEC, and PDAC are the cancer types where IGF2BP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.251	0.740	.001	25	view →
UCEC	DFS	Median	All	0.833	1.000	.005	8	view →
PDAC	OS	Quartile	III,IV	0.264	0.868	.006	7	view →
LUAD	OS	Quartile	II,III,IV	0.299	0.709	.017	3	view →
HNSC	DFS	Quartile	III,IV	0.903	1.000	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IGF2BP1–CCRCC (DFS)

Open the CCRCC breakdown →